Skip header and navigation

Refine By

12 records – page 1 of 2.

[Dynamics of morbidity of the thyroid gland cancer. Evolution of views on its diagnosis and treatment (according to material of the clinic for 50 years)]

https://arctichealth.org/en/permalink/ahliterature19481
Source
Klin Khir. 2001 Jun;(6):50-3
Publication Type
Article
Date
Jun-2001
Author
M P Cheren'ko
O V Mamonov
Source
Klin Khir. 2001 Jun;(6):50-3
Date
Jun-2001
Language
Ukrainian
Publication Type
Article
Keywords
Carcinoma - diagnosis - mortality - surgery
Catchment Area (Health)
English Abstract
Female
Humans
Male
Middle Aged
Retrospective Studies
Survival Rate
Thyroid Neoplasms - diagnosis - mortality - surgery
Ukraine - epidemiology
Abstract
For 50 years 603 patients with the thyroid gland cancer were operated on, to whom 715 operative interventions were done. Before the Chernobyl disaster 395 patients were examined, after her--208. Differentiated forms of the thyroid gland cancer were diagnosed in 97.3% of patients, including papillary one--in 83.3%, follicular--in 14%. After the Chernobyl disaster the thyroid gland cancer diagnosis had improved significantly, it had become revealed on early stage. There were 5.6% patients with cancer operated for the thyroid gland diseases for 50 years (5%--before the disaster and 7.8%--after her). The clinical course of differentiated thyroid gland cancer permits to perform organpreserving operation no less than hemithyroidectomy in patients with T1-2N0M0 stage of the disease. The five-year survival index of patients with differentiated cancer had constituted 89%, the ten-year one--84%.
PubMed ID
11688268 View in PubMed
Less detail

[Effectiveness and monitoring of breast cancer screening programs]

https://arctichealth.org/en/permalink/ahliterature22980
Source
Epidemiol Prev. 1995 Dec;19(65):310-7
Publication Type
Article
Date
Dec-1995
Author
E. Paci
N E Day
Author Affiliation
Unità Operativa di Epidemiologia, Centro per lo Studio e la Prevenzione Oncologica, Firenze.
Source
Epidemiol Prev. 1995 Dec;19(65):310-7
Date
Dec-1995
Language
Italian
Publication Type
Article
Keywords
Adult
Breast - pathology
Breast Neoplasms - diagnosis - mortality - pathology
Carcinoma - diagnosis - mortality - pathology
English Abstract
Female
Health promotion
Humans
Italy - epidemiology
Middle Aged
Neoplasm Staging
Prognosis
Abstract
Several experimental and non experimental studies have shown that mammography every 2-3 years can reduce mortality for breast cancer in women over 50 of about the 30%. On this basis, in the last few years several programmes, population-based, have been organised at Regional and National level in Europe. In this paper the main process indicators useful to assess early the impact of a screening programme are discussed. The proposal of a system for the programme evaluation is mainly based on the experience of the Two County Study, in Sweden, the most important randomised clinical trial in this field.
PubMed ID
8852080 View in PubMed
Less detail

Endoscopic screening during 17 years for gastric stump carcinoma. A prospective clinical trial.

https://arctichealth.org/en/permalink/ahliterature24713
Source
Scand J Gastroenterol. 1991 Oct;26(10):1020-6
Publication Type
Article
Date
Oct-1991
Author
C. Staël von Holstein
S. Eriksson
B. Huldt
E. Hammar
Author Affiliation
Dept. of Surgery, Lund University, Sweden.
Source
Scand J Gastroenterol. 1991 Oct;26(10):1020-6
Date
Oct-1991
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Carcinoma - diagnosis - mortality
Cohort Studies
Duodenal Neoplasms - surgery
Female
Gastrectomy
Gastroscopy
Humans
Male
Middle Aged
Prospective Studies
Research Support, Non-U.S. Gov't
Risk factors
Stomach Neoplasms - diagnosis - mortality
Stomach Ulcer - surgery
Sweden - epidemiology
Abstract
In an attempt to reduce mortality in gastric stump carcinoma a defined cohort of operated peptic ulcer patients was followed up with an endoscopic screening programme. From 1930 and through 1960, 1575 patients were operated on for peptic ulcer disease at the Dept. of Surgery in Lund, Sweden. Of 838 still alive in January 1973, 682 were selected for geographical reasons and were offered endoscopic screening with biopsy at regular intervals. Three hundred and fifty-four patients came to the first examination. The follow-up programme was individualized thereafter with screening at 1- to 3-year intervals, depending on endoscopic and histologic findings. The remaining patients have, since then, constituted a control group, followed up only through death certificates and the Swedish Cancer Registry. By December 1989, 202 patients in the screening group had died and 320 in the control group. During the 17 years of follow-up 12 patients in the screening group died of gastric cancer, compared with 14 in the control group, even though 17 cases of early gastric cancer were diagnosed and operated on in the first group, compared with only 2 in the latter. We conclude that regular endoscopic screening does not reduce gastric cancer mortality and can thus not be recommended in asymptomatic patients previously subjected to partial gastric resection due to peptic ulcer disease.
PubMed ID
1947767 View in PubMed
Less detail

Non-attendance in breast cancer screening is associated with unfavourable socio-economic circumstances and advanced carcinoma.

https://arctichealth.org/en/permalink/ahliterature18003
Source
Int J Cancer. 2004 Feb 20;108(5):754-60
Publication Type
Article
Date
Feb-20-2004
Author
Sophia Zackrisson
Ingvar Andersson
Jonas Manjer
Lars Janzon
Author Affiliation
Department of Community Medicine, Unit of Epidemiology, Lund University, Malmö University Hospital, Malmö, Sweden. sophia.zackrisson@smi.mas.lu.se
Source
Int J Cancer. 2004 Feb 20;108(5):754-60
Date
Feb-20-2004
Language
English
Publication Type
Article
Keywords
Aged
Breast Neoplasms - diagnosis - mortality - pathology
Carcinoma - diagnosis - mortality - pathology
Comparative Study
Female
Humans
Mammography - psychology - statistics & numerical data
Mass Screening
Middle Aged
Odds Ratio
Patient Acceptance of Health Care - statistics & numerical data
Patient Compliance - statistics & numerical data
Research Support, Non-U.S. Gov't
Risk factors
Socioeconomic Factors
Survival Rate
Sweden
Abstract
Our first objective was to assess changes in non-attendance, proportion of advanced breast cancer and survival in Malmö Mammographic Service Screening Program, MMSSP, compared to a former trial, Malmö Mammographic Screening Trial, MMST. Our second objective was to describe non-attenders in MMSSP in socio-economic terms and risk for advanced breast cancer compared to attenders. Information from hospital and national registers was used to identify 33,800 women invited to service screening in MMSSP 1990-93. Attendance rates at first screening, the proportion of advanced breast cancers (Stage II-IV) and survival among non-attenders in MMSSP were compared to the non-attenders and with the control group of the former trial, MMST. Various socio-economic factors were assessed as potential predictors of non-attendance in MMSSP. Odds ratios (OR) and 95% confidence interval (CI) were computed. Incidence of breast cancer during a 10-year-period, relative risks and 95% CI among non-attenders compared to attenders in MMSSP were computed. Attendance rates were significantly lower in MMSSP but a lower proportion of advanced breast cancers and a somewhat better survival among breast cancer cases (not significant) was seen in non-attenders in MMSSP compared to MMST. In MMSSP non-attendance was associated with being unmarried, being born abroad, being not currently employed, crowded housing conditions and low income. Incidence of advanced breast cancer was significantly higher among non-attenders than among attenders. Attendance has decreased over time and potential reasons are discussed. Stage distribution and survival among non-attenders seem to have improved. Several socio-economic factors predict non-attendance and non-attenders are at higher risk for advanced breast cancer.
PubMed ID
14696103 View in PubMed
Less detail

Palliation of non-resectable carcinoma of the cardia and oesophagus by argon beam coagulation.

https://arctichealth.org/en/permalink/ahliterature18654
Source
Dan Med Bull. 2002 Nov;49(4):346-9
Publication Type
Article
Date
Nov-2002
Author
Jens Ravn Eriksen
Author Affiliation
jravn@dadlnet.dk
Source
Dan Med Bull. 2002 Nov;49(4):346-9
Date
Nov-2002
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Argon - therapeutic use
Balloon Dilatation
Blood Transfusion
Carcinoma - diagnosis - mortality - therapy
Comparative Study
Denmark - epidemiology
Endoscopy
Esophageal Neoplasms - diagnosis - mortality - therapy
Esophageal Perforation - diagnosis - mortality - therapy
Female
Follow-Up Studies
Heart Neoplasms - diagnosis - mortality - therapy
Humans
Laser Coagulation
Length of Stay
Male
Middle Aged
Palliative Care
Patient Admission
Radioisotopes - therapeutic use
Radiotherapy, Adjuvant
Retrospective Studies
Survival Analysis
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Abstract
INTRODUCTION: The aim of this study was to describe the argon beam coagulation (ABC) technique in the palliative treatment of patients with nonresectable carcinoma of the cardia and oesophagus and this treatments needs, complications and tolerance. METHODOLOGY: A retrospective evaluation of 31 patients referred for palliation by ABC over a period of nearly four years (1.1.98-31.8.01). RESULTS: Twenty-two men and nine women, median age 72 years (range 49-91 years), underwent a total of 163 treatments and a median of five treatments per patient (range 1-18). Recanalisation enabling passage of the scope was achieved in 89% of treatments, and most of these patients had dysphagia grade = 2. The median range between reinterventions was 25 days (range 1-175 days). Perforation was seen in three patients and in 1.8% of treatments; procedure related mortality was 1.2%. The median hospital stay for every treatment was two days (range 1-27 days) and the median inpatient stay as a proportion of survival time was 8%. The median survival was 190 days (range 7-612 days) with the 1-year survival 19%. DISCUSSION: ABC is a well-tolerated, safe and effective treatment in patients with non-resectable cancer of the oesophagus or cardia and offers an acceptable complication rate and number of reinterventions compared with laser and stent placement. The technique is easy and cheap, and requires no further restrictions than conventional monopolar electro coagulation does. Prospective randomised trials comparing the efficacy of the different palliative treatments for patients with oesophagogastric cancer are needed.
PubMed ID
12553168 View in PubMed
Less detail

Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital.

https://arctichealth.org/en/permalink/ahliterature21466
Source
Acta Obstet Gynecol Scand. 1998 Aug;77(7):777-81
Publication Type
Article
Date
Aug-1998
Author
T. Bjørge
A. Engeland
K. Sundfør
C G Tropé
Author Affiliation
Department of Gynecologic Oncology, The Norwegian Radium Hospital, Montebello, Oslo.
Source
Acta Obstet Gynecol Scand. 1998 Aug;77(7):777-81
Date
Aug-1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma - diagnosis - mortality - therapy
Female
Humans
Middle Aged
Multivariate Analysis
Neoplasm Staging
Norway
Ovarian Neoplasms - diagnosis - mortality - therapy
Prognosis
Research Support, Non-U.S. Gov't
Survival Analysis
Treatment Outcome
Abstract
BACKGROUND: Ovarian cancer patients have a poor prognosis. In Norway, however, the prognosis has improved steadily since the 1950s, the age-adjusted 5-year relative survival reaching 37% in 1989 93. The aim of the present study was to explore the prognosis of patients with epithelial ovarian cancer diagnosed during 1975-94 (the prepaclitaxel period) and treated at The Norwegian Radium Hospital. METHOD: Relative risks (RR) of dying and 95% confidence intervals (95% CI) were derived from multivariate Cox proportional hazards regression models. RESULTS: A total of 2,769 patients with epithelial ovarian cancer were included in the present study. Altogether 54% of the patients were diagnosed with advanced stage disease (stages III and IV), whereas 32% were diagnosed with stage I disease. The prognosis of the patients improved from the 1970s to the 1990s, mainly due to increased short-term survival. In multivariate survival analysis, the RR of dying decreased with period of diagnosis. An RR of 0.77 (95% CI=0.66-0.89) was seen in 1990-94 compared with 1975-79. CONCLUSION: The short-term survival of patients with epithelial ovarian cancer improved from the late 1970s to the early 1990s. However, no major improvement in the long-term survival was seen.
PubMed ID
9740528 View in PubMed
Less detail

Prognostic nomograms to predict oncological outcome of thyroid cancers.

https://arctichealth.org/en/permalink/ahliterature106528
Source
J Clin Endocrinol Metab. 2013 Dec;98(12):4768-75
Publication Type
Article
Date
Dec-2013
Author
K Alok Pathak
Andrea Mazurat
Pascal Lambert
Thomas Klonisch
Richard W Nason
Author Affiliation
MS, DNB, FRCS(Glasg.), FRCSEd, MNAMS, FRCSC,University of Manitoba, Head and Neck Surgical Oncologist, Cancer Care Manitoba, GF 440 A, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada. alok.pathak@cancercare.mb.ca.
Source
J Clin Endocrinol Metab. 2013 Dec;98(12):4768-75
Date
Dec-2013
Language
English
Publication Type
Article
Keywords
Adult
Cancer Care Facilities
Carcinoma - diagnosis - mortality - prevention & control - therapy
Carcinoma, Papillary - diagnosis - mortality - prevention & control - therapy
Cohort Studies
Female
Follow-Up Studies
Humans
Incidence
Lymphatic Metastasis
Male
Manitoba - epidemiology
Models, Biological
Neoplasm Recurrence, Local - epidemiology - mortality - prevention & control - therapy
Neoplasm Staging
Neoplasm, Residual - diagnosis - mortality - pathology - therapy
Prognosis
Risk
Survival Analysis
Thyroid Neoplasms - diagnosis - mortality - prevention & control - therapy
Abstract
Thyroid cancers represent a conglomerate of diverse histological types with equally variable prognosis. There is no reliable prognostic model to predict the risks of relapse and death for different types of thyroid cancers.
The purpose of this study was to build prognostic nomograms to predict individualized risks of relapse and death of thyroid cancer within 10 years of diagnosis based on patients' prognostic factors.
Competing risk subhazard models were used to develop prognostic nomograms based on the information on individual patients in a population-based thyroid cancer cohort followed up for a median period of 126 months. Analyses were conducted using R version 2.13.2. The R packages cmprsk10, Design, and QHScrnomo were used for modeling, developing, and validating the nomograms for prediction of patients' individualized risks of relapse and death of thyroid cancer.
This study was performed at CancerCare Manitoba, the sole comprehensive cancer center for a population of 1.2 million.
Participants were a population-based cohort of 2306 consecutive thyroid cancers observed in 2296 patients in the province of Manitoba, Canada, during 1970 to 2010.
Outcomes were discrimination (concordance index) and calibration curves of nomograms.
Our cohort of 570 men and 1726 women included 2155 (93.4%) differentiated thyroid cancers. On multivariable analysis, patient's age, sex, tumor histology, T, N, and M stages, and clinically or radiologically detectable posttreatment gross residual disease were independent determinants of risk of relapse and/or death. The individualized 10-year risks of relapse and death of thyroid cancer in the nomogram were predicted by the total of the weighted scores of these determinants. The concordance indices for prediction of thyroid cancer-related deaths and relapses were 0.92 and 0.76, respectively. The calibration curves were very close to the diagonals.
We have successfully developed prognostic nomograms for thyroid cancer with excellent discrimination (concordance indices) and calibration.
Notes
Comment In: J Clin Endocrinol Metab. 2013 Dec;98(12):4673-524311794
PubMed ID
24152685 View in PubMed
Less detail

Randomised study of screening for colorectal cancer with faecal-occult-blood test.

https://arctichealth.org/en/permalink/ahliterature22396
Source
Lancet. 1996 Nov 30;348(9040):1467-71
Publication Type
Article
Date
Nov-30-1996
Author
O. Kronborg
C. Fenger
J. Olsen
O D Jørgensen
O. Søndergaard
Author Affiliation
Department of Surgery A, Odense University Hospital, Denmark.
Source
Lancet. 1996 Nov 30;348(9040):1467-71
Date
Nov-30-1996
Language
English
Publication Type
Article
Keywords
Adenoma - diagnosis - mortality - prevention & control
Aged
Carcinoma - diagnosis - mortality - prevention & control
Cause of Death
Colonoscopy
Colorectal Neoplasms - diagnosis - mortality - prevention & control
Denmark - epidemiology
Female
Follow-Up Studies
Humans
Male
Mass Screening
Middle Aged
Occult Blood
Research Support, Non-U.S. Gov't
Abstract
BACKGROUND: Case-control studies and a voluntary-based follow-up study have suggested that repeated screening with faecal-occult-blood (FOB) tests can lead to a reduction in mortality from colorectal cancer (CRC). The aim of this randomised study was to compare mortality rates after FOB tests every 2 years during a 10-year period with those of unscreened similar controls. METHODS: 140,000 people aged 45-75 years lived in Funen, Denmark, in August, 1985, and were considered for inclusion in our study. Before randomisation we excluded individuals who had CRC or precursor adenomas and those who had taken part in a previous pilot study. Randomisation of 137,485 people in blocks of 14 allocated three per 14 to the screening group (30,967), three per 14 to the control group (30,966), and eight not to be enrolled in the study (75,552). Controls were not told about the study and continued to use health-care facilities as normal. Hemoccult-II blood tests (with dietary restrictions but without rehydration) were sent to screening-group participants. Only those participants who completed the first screening round were invited for further screening--five rounds of screening during a 10-year period. Participants with positive tests were asked to attend to full examination and were offered colonoscopy whenever possible. The primary endpoint was death from CRC. FINDINGS: Of the 30,967 screening-group participants, 20,672 (67%) completed the first screening round and were invited for further screening; more than 90% accepted repeated screenings. During the 10-year study, 481 people in the screening group had a diagnosis of CRC, compared with 483 unscreened controls. There were 205 deaths attributable to CRC in the screening group, compared with 249 deaths in controls. CRC mortality, including deaths attributable to complications from CRC treatment, was significantly lower in the screening group than in controls (mortality ratio 0.82 [95% CI 0.68-0.99]) p = 0.03). INTERPRETATION: Our findings indicate that biennial screening by FOB tests can reduce CRC mortality. This study is being continued to improve its statistical power and to assess the effect of the removal of more precursor adenomas in the screening-group participants than in controls on CRC incidence.
Notes
Comment In: ACP J Club. 1997 May-Jun;126(3):62-3
Comment In: Lancet. 1997 Feb 1;349(9048):356-7; author reply 3589024399
Comment In: Lancet. 1997 Feb 1;349(9048):356; author reply 3589024398
Comment In: Lancet. 1997 Feb 1;349(9048):357-89024401
Comment In: Lancet. 1997 Feb 1;349(9048):357; author reply 3589024400
PubMed ID
8942774 View in PubMed
Less detail

[RESULTS OF DIAGNOSTICS AND TREATMENT OF ADRENOCORTICAL CANCER].

https://arctichealth.org/en/permalink/ahliterature266606
Source
Vestn Khir Im I I Grek. 2015;174(3):29-39
Publication Type
Article
Date
2015
Author
P N Romashchenko
N A Maistrenko
R V Orlova
A I Babich
Source
Vestn Khir Im I I Grek. 2015;174(3):29-39
Date
2015
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adrenal Cortex Neoplasms - diagnosis - mortality - therapy
Adrenalectomy - methods
Adrenocortical Carcinoma - diagnosis - mortality - therapy
Adult
Aged
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Neoplasm Staging
Nephrectomy - methods
Prognosis
Retrospective Studies
Russia - epidemiology
Survival Rate - trends
Young Adult
Abstract
The results of examination and treatment of 96 patients with adrenocortical cancer (ACC) were analyzed. Local forms of ACC (I and II stages (T1-2N0M0) were found in 19 patients, locally advanced forms (III stage (T1-4NIM0; T3-4N0M0) - in 62 cases and metastatic forms of ACC (IV stage (TxNxM1) - in 15 patients. The diagnostic approach to ACC was optimized. It allowed identifying ACC on early stages of oncological process and staging of oncological process preoperatively in order to justify a rational treatment option. Surgical interventions were performed on 85 patients. The authors used an open access in 75 patients and endovideosurgical - in 10. The most common way of surgery was to remove an affected adrenal gland with fat of upper paranephrium and regional for adrenal lymph nodes (n=56). The adrenalectomy and nephrectomy were fulfilled on 23 patients. A removal of the right adrenal with tumor and thrombus of the interior vena cava was carried out in 2 patients. Some patients (n=4) underwent the explorative interventions. Combined treatment was applied in 28 patients with ACC of III stage. This gave a possibility to increase their life-span from 17,5±8,4 to 36,3±6 months. The overall 3-year survival rate for patients with ACC was 41,2% and 5-year survival observed in 18,7%. An application of modified treatment-and-diagnostics algorithm allowed increasing detection of patients with local and locally advanced forms of ACC in 2,5 times. Therefore, the application of rational treatment options have reduced the number of intraoperative complications from 38,8% to 10,2% and postoperative complication rates- from 61,1% to 20,4%, the lethality :rate - from 7,1% to 0% in early postoperative period. These measures have increased the life-span and life quality in 2 times.
PubMed ID
26390585 View in PubMed
Less detail

Screening and cervical cancer cure: population based cohort study.

https://arctichealth.org/en/permalink/ahliterature126544
Source
BMJ. 2012;344:e900
Publication Type
Article
Date
2012
Author
Bengt Andrae
Therese M-L Andersson
Paul C Lambert
Levent Kemetli
Lena Silfverdal
Björn Strander
Walter Ryd
Joakim Dillner
Sven Törnberg
Pär Sparén
Author Affiliation
Centre for Research and Development, Uppsala University/County Council of Gävleborg, S-80188 Gävle, Sweden. bengt.andrae@ki.se
Source
BMJ. 2012;344:e900
Date
2012
Language
English
Publication Type
Article
Keywords
Adult
Bias (epidemiology)
Carcinoma - diagnosis - mortality - pathology - prevention & control
Cohort Studies
Early Detection of Cancer
Female
Humans
Mass Screening
Middle Aged
Models, Theoretical
Neoplasm Staging
Outcome Assessment (Health Care) - statistics & numerical data
Prognosis
Survival Rate
Sweden - epidemiology
Time Factors
Uterine Cervical Neoplasms - diagnosis - mortality - pathology - prevention & control
Vaginal Smears
Young Adult
Abstract
To determine whether detection of invasive cervical cancer by screening results in better prognosis or merely increases the lead time until death.
Nationwide population based cohort study.
Sweden.
All 1230 women with cervical cancer diagnosed during 1999-2001 in Sweden prospectively followed up for an average of 8.5 years.
Cure proportions and five year relative survival ratios, stratified by screening history, mode of detection, age, histopathological type, and FIGO (International Federation of Gynecology and Obstetrics) stage.
In the screening ages, the cure proportion for women with screen detected invasive cancer was 92% (95% confidence interval 75% to 98%) and for symptomatic women was 66% (62% to 70%), a statistically significant difference in cure of 26% (16% to 36%). Among symptomatic women, the cure proportion was significantly higher for those who had been screened according to recommendations (interval cancers) than among those overdue for screening: difference in cure 14% (95% confidence interval 6% to 23%). Cure proportions were similar for all histopathological types except small cell carcinomas and were closely related to FIGO stage. A significantly higher cure proportion for screen detected cancers remained after adjustment for stage at diagnosis (difference 15%, 7% to 22%).
Screening is associated with improved cure of cervical cancer. Confounding cannot be ruled out, but the effect was not attributable to lead time bias and was larger than what is reflected by down-staging. Evaluations of screening programmes should consider the assessment of cure proportions.
Notes
Cites: Stat Med. 1999 Feb 28;18(4):441-5410070685
Cites: Cancer. 1995 Nov 15;76(10 Suppl):1948-558634986
Cites: Eur J Cancer Prev. 2005 Oct;14(5):459-6616175050
Cites: J Intern Med. 2006 Aug;260(2):103-1716882274
Cites: Biostatistics. 2007 Jul;8(3):576-9417021277
Cites: Int J Cancer. 2007 Nov 1;121(9):2052-917640061
Cites: J Psychosom Obstet Gynaecol. 2008 Mar;29(1):23-3118266164
Cites: Int J Gynaecol Obstet. 2008 May;101(2):205-1018199437
Cites: J Natl Cancer Inst. 2008 May 7;100(9):605-618445817
Cites: J Natl Cancer Inst. 2008 May 7;100(9):622-918445828
Cites: Psychooncology. 2008 Jun;17(6):561-917886262
Cites: Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):204-918093720
Cites: Br J Cancer. 2008 Sep 23;99 Suppl 1:S63-418813263
Cites: Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1070-619318437
Cites: Annu Rev Med. 2009;60:125-3718803476
Cites: BMJ. 2009;339:b296819638651
Cites: Am J Obstet Gynecol. 2009 Aug;201(2):188.e1-719560117
Cites: Eur J Cancer. 2009 Oct;45(15):2640-819695864
Cites: Eur J Cancer. 2009 Oct;45(15):2671-819695867
Cites: J Med Screen. 2009;16(4):199-20420054095
Cites: J Natl Cancer Inst. 2010 May 5;102(9):605-1320413742
Cites: Int J Epidemiol. 2010 Jun;39(3):757-6520176587
Cites: BMJ. 2010;341:c454320843937
Cites: Eur J Obstet Gynecol Reprod Biol. 2010 Oct;152(2):200-420667643
Cites: BMJ. 2011;342:d153921454449
Cites: JAMA. 2011 Jun 8;305(22):2295-30321642681
Cites: Int J Cancer. 2012 Feb 15;130(4):937-4721437898
Cites: Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):571-710076130
Cites: Lancet. 2002 Mar 9;359(9309):881-411897304
Cites: Semin Surg Oncol. 1994 Jan-Feb;10(1):31-468115784
Cites: J Clin Oncol. 1995 Mar;13(3):715-257884431
Cites: Obstet Gynecol. 1995 Jun;85(6):1017-217770247
Comment In: BMJ. 2012;344:e80422381675
PubMed ID
22381677 View in PubMed
Less detail

12 records – page 1 of 2.